Skip to main content
×
×
Home

Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons

  • Marjaana Koponen (a1), Anna-Maija Tolppanen (a2), Heidi Taipale (a1), Antti Tanskanen (a3), Jari Tiihonen (a4), Kristina Johnell (a5), Johan Fastbom (a6), Riitta Ahonen (a7) and Sirpa Hartikainen (a1)...
Abstract
Background

Behavioural and psychological symptoms of dementia are frequently treated with antipsychotics.

Aims

To determine the incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease.

Method

Cohort of all community-dwellers in Finland diagnosed with Alzheimer's disease in 2005 and matched controls. All antipsychotics dispensed between 1995 and 2009 were extracted from the Finnish National Prescription Register.

Results

Altogether 1996/6087 (32.8%) persons with Alzheimer's disease initiated antipsychotic use. The incidence of antipsychotic use was fivefold among persons with Alzheimer's disease compared with controls, started to increase 2–3 years before diagnosis and was highest during the first 6 months after diagnosis.

Conclusions

A distinct increase in antipsychotic initiations occurs in the same time window as Alzheimer's disease diagnosis.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons
      Available formats
      ×
Copyright
Corresponding author
Marjaana Koponen, MSc, Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, P.O. Box. 1627, FI-70211 Kuopio, Finland. Email: marjaana.koponen@uef.fi
Footnotes
Hide All

Declaration of interest

J.T. received personal fees from AstraZeneca, Janssen-Cilag, Otsuka, Bristol-Myers Squibb, Lundbeck, Organon, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Pfizer, Novartis and receives a grant from Stanley Foundation, outside the submitted work.

Footnotes
References
Hide All
1 Lyketsos, CG, Lopez, O, Jones, B, Fitzpatrick, AL, Breitner, J, DeKosky, S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; 288: 1475–83.
2 Steinberg, M, Shao, H, Zandi, P, Lyketsos, CG, Welsh-Bohmer, KA, Norton, MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008; 23: 170–7.
3 Laitinen, ML, Bell, JS, Lavikainen, P, Lönnroos, E, Sulkava, R, Hartikainen, S. Nationwide study of antipsychotic use among community-dwelling persons with Alzheimer's disease in Finland. Int Psychogeriatr 2011; 23: 1623–31.
4 Calvo-Perxas, L, de Eugenio, RM, Marquez-Daniel, F, Martinez, R, Serena, J, Turbau, J, et al. Profile and variables related to antipsychotic consumption according to dementia subtypes. Int Psychogeriatr 2012; 24: 940–7.
5 Rattinger, GB, Burcu, M, Dutcher, SK, Chhabra, PT, Rosenberg, PB, Simoni-Wastila, L, et al. Pharmacotherapeutic management of dementia across settings of care. J Am Geriatr Soc 2013; 61: 723–33.
6 Schneider, LS, Dagerman, KS, Insel, P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43.
7 Gill, SS, Bronskill, SE, Normand, SL, Anderson, GM, Sykora, K, Lam, K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146: 775–86.
8 Kales, HC, Kim, HM, Zivin, K, Valenstein, M, Seyfried, LS, Chiang, C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169: 71–9.
9 Rochon, PA, Stukel, TA, Sykora, K, Gill, S, Garfinkel, S, Anderson, GM, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005; 165: 1882–8.
10 Jalbert, JJ, Eaton, CB, Miller, SC, Lapane, KL. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc 2010; 11: 120–7.
11 Gill, SS, Rochon, PA, Herrmann, N, Lee, PE, Sykora, K, Gunraj, N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445.
12 Wu, CS, Wang, SC, Gau, SS, Tsai, HJ, Cheng, YC. Association of stroke with the receptor-binding profiles of antipsychotics – a case-crossover study. Biol Psychiatry 2013; 73: 414–21.
13 Livingston, G, Walker, AE, Katona, CL, Cooper, C. Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study. J Neurol Neurosurg Psychiatry 2007; 78: 25–9.
14 Vigen, CL, Mack, WJ, Keefe, RS, Sano, M, Sultzer, DL, Stroup, TS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 2011; 168: 831–9.
15 Rosenberg, PB, Mielke, MM, Han, D, Leoutsakos, JS, Lyketsos, CG, Rabins, PV, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int J Geriatr Psychiatry 2012; 27: 1248–57.
16 Lonergan, E, Luxenberg, J, Colford, J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002; 2: CD002852.
17 Ballard, C, Waite, J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD003476.
18 Schneider, LS, Dagerman, K, Insel, PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14: 191210.
19 Maher, AR, Maglione, M, Bagley, S, Suttorp, M, Hu, JH, Ewing, B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306: 1359–69.
20 APA Work Group on Alzheimer's Disease and other Dementias, Rabins, PV, Blacker, D, Rovner, BW, Rummans, T, Schneider, LS, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. 2nd ed. Am J Psychiatry 2007; 164: 556.
21 Working group set up by the Finnish Medical Society Duodecim, Societas Gerontologica Fennica, the Finnish Neurological Society, Finnish Psychogeriatric Association and the Finnish Association for General Practice. Memory disorders. Current Care Guidelines, The Finnish Medical Society Duodecim, 2014 (http://www.kaypahoito.fi).
22 National Institute for Health and Clinical Excellence. Dementia: Supporting People with Dementia and their Carers in Health and Social Care. NICE clinical guideline 42. NICE, 2012.
23 Tolppanen, AM, Taipale, H, Koponen, M, Lavikainen, P, Tanskanen, A, Tiihonen, J, et al. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research – the Medication use among persons with Alzheimer's disease (MEDALZ-2005) study. Clin Epidemiol 2013; 5: 277–85.
24 McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939–44.
25 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
26 WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health, 2013. (http://www.whocc.no/atc_ddd_index/).
27 World Health Organization. The IDC-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. WHO, 1993.
28 World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 9th Revision. WHO, 1975.
29 World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 8th Revision. WHO, 1965.
30 Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83.
31 Rosenberg, PB, Mielke, MM, Appleby, BS, Oh, ES, Geda, YE, Lyketsos, CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry 2013; 21: 685–95.
32 Rockwood, K, Cosway, S, Carver, D, Jarrett, P, Stadnyk, K, Fisk, J. The risk of dementia and death after delirium. Age Ageing 1999; 28: 551–6.
33 Rahkonen, T, Luukkainen-Markkula, R, Paanila, S, Sivenius, J, Sulkava, R. Delirium episode as a sign of undetected dementia among community dwelling elderly subjects: a 2 year follow up study. J Neurol Neurosurg Psychiatry 2000; 69: 519–21.
34 Davis, DH, Muniz Terrera, G, Keage, H, Rahkonen, T, Oinas, M, Matthews, FE, et al. Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain 2012; 135: 2809–16.
35 Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement 2014; 10: e4792.
36 Martinez, C, Jones, RW, Rietbrock, S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open 2013; 3: e002080.
37 Taipale, H, Koponen, M, Tanskanen, A, Tolppanen, AM, Tiihonen, J, Hartikainen, S. Antipsychotic doses among community-dwelling persons with Alzheimer disease in Finland. J Clin Psychopharmacol 2014; 34: 435–40.
38 Taipale, H, Koponen, M, Tanskanen, A, Tolppanen, AM, Tiihonen, J, Hartikainen, S. Antipsychotic polypharmacy among a nationwide sample of community-dwelling persons with Alzheimer's disease. J Alzheimers Dis 2014; 41: 1223–8.
39 Inouye, SK, Westendorp, RG, Saczynski, JS. Delirium in elderly people. Lancet 2014; 383: 911–22.
40 Hermes, ED, Sernyak, M, Rosenheck, R. Use of second-generation antipsychotic agents for sleep and sedation: a provider survey. Sleep 2013; 36: 597600.
41 Working group set up by the Finnish Medical Society Duodecim and the Finnish Sleep Research Society. Current Care Guidelines: Insomnia. 2015 (http://www.kaypahoito.fi).
42 Rikala, M, Hartikainen, S, Sulkava, R, Korhonen, MJ. Validity of the Finnish Prescription Register for measuring psychotropic drug exposures among elderly Finns: a population-based intervention study. Drugs Aging 2010; 27: 337–49.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 1
Total number of PDF views: 24 *
Loading metrics...

Abstract views

Total abstract views: 138 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 25th June 2018. This data will be updated every 24 hours.

Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons

  • Marjaana Koponen (a1), Anna-Maija Tolppanen (a2), Heidi Taipale (a1), Antti Tanskanen (a3), Jari Tiihonen (a4), Kristina Johnell (a5), Johan Fastbom (a6), Riitta Ahonen (a7) and Sirpa Hartikainen (a1)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *